Editorial Comment From Dr. Kato to Post-Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma.
- DOI
- 10.1111/iju.70573
- Published
- 2026 Sep
- Container
- International journal of urology : official journal of the Japanese Urological Association
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/iju.70573,
title = {Editorial Comment From Dr. Kato to Post-Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma.},
author = {Kato T and Matsukawa A and Nonomura N},
year = {2026},
journal = {International journal of urology : official journal of the Japanese Urological Association},
doi = {10.1111/iju.70573},
url = {https://doi.org/10.1111/iju.70573}
}RIS
TY - JOUR TI - Editorial Comment From Dr. Kato to Post-Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma. AU - Kato T AU - Matsukawa A AU - Nonomura N PY - 2026 JO - International journal of urology : official journal of the Japanese Urological Association DO - 10.1111/iju.70573 UR - https://doi.org/10.1111/iju.70573 ER -
APA
T, K., A, M., & N, N. (2026). Editorial Comment From Dr. Kato to Post-Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma.. International journal of urology : official journal of the Japanese Urological Association. https://doi.org/10.1111/iju.70573
Source records
- pubmed · retrieved 2026-09-26T23:55:39.914Z